Paediatric burns

2019 ◽  
pp. 303-310
Author(s):  
Jong Lee
Keyword(s):  
Resource Allocation ◽  
Hospital Care ◽  
Burn Injury ◽  
Term Therapy ◽  
Burn Care ◽  
Paediatric Burns ◽  
Informatics Infrastructure ◽  
Long Term Therapy ◽  
The Cost

The burden of burn injury, however trivial it may seem, is devastating physically, psychologically and also financially. Health economists find it difficult to quantify the costs of acute care and almost impossible to define the cost of the needed adjustment after recovery. Burns patients often require long-term therapy and out patient hospital care, and frequently, re-admission for reconstructive surgery. Calculating the cost of burn care is important for reimbursement, resource allocation and achieving efficiency by prudent cost analysis. Realistic cost estimates of burn care require robust data collection and a reliable informatics infrastructure.

scholarly journals Natriuretic Peptides: Role in Current Cardiology

2015 ◽  
Vol 70 (5) ◽  
pp. 568-572 ◽  
Author(s):  
G. A. Burnasheva ◽  
D. A. Napalkov
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptides ◽  
Left Ventricular ◽  
Term Therapy ◽  
Patients With Heart Failure ◽  
Acute Decompensation ◽  
Definition Of ◽  
Long Term Therapy ◽  
The Cost

Natriuretic peptides were discovered in 50–70s of the XX century. BNP was more diagnostically and prognostically significant, as it is secreted directly into the ventricles of the heart. The studies demonstrated a high predictive value of increasing the level of BNP in acute decompensation of heart failure and in patients with chronic heart failure in a study of Val-HeFT. It was demonstrated that monitoring the level of NT-proBNP can be used for the selection of optimal therapy, affect the course and outcome of the disease, and reduce the cost of treatment. The next step in learning BNP was to undertake attempts of their use in the therapy of heart failure. Long-term therapy BNP (drug nesiritide) improved left ventricular remodelling in patients with stable heart failure. Currently the definition of the levels of BNP and NT-proBNP is used for the diagnosis and management of patients with heart failure.

scholarly journals Fluvoxamina: profilo farmacoeconomico

2001 ◽  
Vol 2 (3) ◽  
pp. 175-184
Author(s):  
Mario Eandi
Keyword(s):  
Cost Minimization ◽  
Economic Benefits ◽  
Pharmacoeconomic Evaluation ◽  
Term Therapy ◽  
Purchase Cost ◽  
Antidepressant Use ◽  
Differential Costs ◽  
Long Term Therapy ◽  
The Cost

In this study we mean to outline a brief pharmacoeconomic review of fluvoxamine, considering only its antidepressant use. Essential objective is to highlight all the variables of cost effectiveness, tolerance and safety that can lead some types of differential costs. This study analyses the epidemiology and the economic burden of depression and a pharmacoeconomic profile of fluvoxamine, with its characteristics of effectiveness, tolerance, safety and handiness. The pharmacoeconomic evaluation is conducted according to the cost minimization analysis (CMA), considering fluvoxamine, Selective Serotonine Reuptake Inhibitors (SSRI) and antidepressant tricycic as native treatments. Fluvoxamine differs from the others SSRI far the purchase cost and it’s more convenient than the antidepressant tricycic treatment, especially for long term therapy. Economic benefits can be distributed in a balanced way between the Italian national healthcare system (NACS), the society and the patients.

Large (But Simple) Trials: When Are They Justified

1981 ◽  
Author(s):  
C L Meinert
Keyword(s):  
Data Collection ◽  
Chronic Condition ◽  
Large Scale ◽  
Extended Period ◽  
Multicenter Trial ◽  
Term Therapy ◽  
Major Factors ◽  
Long Term Therapy ◽  
The Cost

Trials, designed to evaluate the therapeutic or prophylactic effect of a treatment on a chronic condition such as heart disease, often require thousands of patients to provide the power required to detect a small but clinically important treatment effect. The complexity and cost of the large scale multicenter trial has made it difficult to obtain the support needed to carry them out. There is a need to find ways to reduce the cost of large scale trials if they are to remain in our armamentarium of evaluation tools, especially in this age of shrinking research budgets. This paper examines the major factors which contribute to the cost of large scale trials and conditions required before it is possible to consider simplified data collection and follow-up procedures. Special emphasis is given to the difficulty scaled down data collection efforts may cause when the safety of the study treatment is in doubt and when the test treatment must be administered over an extended period of time, as in drug trials providing long term therapy for a chronic condition.

Olanzapine in the long-term treatment of schizophrenia

1999 ◽  
Vol 174 (S37) ◽  
pp. 26-29 ◽  
Author(s):  
John Kane
Keyword(s):  
Antipsychotic Drugs ◽  
Antipsychotic Agent ◽  
Term Treatment ◽  
Term Therapy ◽  
Therapeutic Benefits ◽  
Maintenance Medication ◽  
Long Term Treatment ◽  
Long Term Therapy ◽  
The Cost

The primary aim of the long-term treatment of patients with schizophrenia is to prevent relapse, which is costly both in psychological and economic terms. Although with conventional antipsychotic drugs relapse may occur despite compliance with maintenance regimens, the rate of relapse is reduced in compliant patients. However, this benefit is achieved at the cost of side-effects and the risk of developing tardive dyskinesia, even among patients who have taken these drugs for only a year or two. To provide the therapeutic benefits of maintenance medication without its drawbacks, intermittent dosing and long-term therapy with reduced doses of conventional medications have been explored. The atypical antipsychotic agent, olanzapine, has been shown to be effective maintenance medication and has an improved safety profile.

Antithrombotic Therapy for DVT/PE

1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Cost Effective ◽  
Therapeutic Agents ◽  
Great Promise ◽  
Term Therapy ◽  
Low Molecular Weight ◽  
Long Term Therapy

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.

Office-based post-marketing surveillance study on the influence of long term therapy with aripiprazole in patients with schizophrenia

2007 ◽  
Vol 40 (05) ◽  
Author(s):  
M Kungel ◽  
A Engelhardt ◽  
T Spevakné-Göröcs ◽  
M Ebrecht ◽  
C Werner ◽  
...  
Keyword(s):  
Surveillance Study ◽  
Term Therapy ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Long Term Therapy
Sign in / Sign up

Export Citation Format

Share Document